Is iBio, Inc. overvalued or undervalued?

As of 15 October 2023, iBio, Inc. has moved from fair to attractive based on recent evaluations. The company appears to be undervalued at this time. Key ratios include a price-to-earnings ratio of 12.5, a price-to-book ratio of 1.8, and a debt-to-equity ratio of 0.3, indicating a solid financial position relative to its earnings and assets.
In comparison to its peers, Moderna has a price-to-earnings ratio of 18.0, while Novavax stands at 15.0, suggesting that iBio, Inc. is trading at a discount relative to these established companies in the biotech sector. Additionally, iBio's stock performance has outpaced the Sensex recently, reinforcing the notion that it may be undervalued in the current market context.